Publications

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer

Kim D, Sim NS, Woo S, Kim MH, Lee CK, Hong SS, Kim SH, Hwang HK, Kang CM, Lee WJ, Jo JH, Chung T, Hwang S, Kang B, Kim JS, Kwon CI, Kim S, Chon HJ, Kim CG, Park YN, Choi HJ

Clinical and Molecular Hepatology 32(2), 721–736

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, … Park W, …

Nature Medicine 31(2), 466–477

Automated real-world data integration improves cancer outcome prediction

Jee J, Fong C, Pichotta K, Tran TN, Luthra A, Waters M, Fu C, Altoe M, …

Nature 636(8043), 728–736

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GH, … Park W, …

Cancer Cell 42(9), 1614–1629

Early-onset pancreas cancer: clinical descriptors, genomics, and outcomes

Varghese AM, Singh I, Singh R, Kunte S, Chou JF, Capanu M, Wong W, … Park W, …

JNCI: Journal of the National Cancer Institute 113(9), 1194–1202

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Dunbar A, Bolton KL, Devlin SM, Sanchez-Vega F, Gao J, Mones JV, … Park W, …

Blood 137(15), 2103–2113

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma

McIntyre CA, Lawrence SA, Richards AL, Chou JF, Wong W, Capanu M, … Park W, …

Cancer 126(17), 3939–3949

Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection

Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, …

Clinical Cancer Research 26(13), 3239–3247